Anzeige
Mehr »
Donnerstag, 09.10.2025 - Börsentäglich über 12.000 News
Kursrakete 2025: CiTech präsentiert sich u.a. mit DroneShield neben Palantir & Rheinmetall - welche News sind zu erwarten?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AR5F | ISIN: CH0329023102 | Ticker-Symbol: IMR
Tradegate
09.10.25 | 09:49
3,095 Euro
+1,98 % +0,060
1-Jahres-Chart
AC IMMUNE SA Chart 1 Jahr
5-Tage-Chart
AC IMMUNE SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,0153,15011:42
3,0153,12511:36

Aktuelle News zur AC IMMUNE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.09.AC Immune's Alzheimer's immunotherapy shows promising results82
25.09.AC Immune SA: Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine301Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054...
► Artikel lesen
AC IMMUNE Aktie jetzt für 0€ handeln
04.09.AC Immune cuts workforce by 30%, trims pipeline to preserve cash43
04.09.AC Immune SA - 6-K, Report of foreign issuer7
04.09.AC Immune SA: AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway459AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce...
► Artikel lesen
05.08.AC Immune: EPS verfehlt Schätzungen um 0,04 CHF - Umsatz schlechter als erwartet113
05.08.AC Immune SA: AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update403AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical...
► Artikel lesen
05.08.AC Immune SA - 6-K, Report of foreign issuer8
20.06.AC Immune SA - 6-K, Report of foreign issuer72
11.06.AC Immune SA - 6-K, Report of foreign issuer30
19.05.AC Immune SA - 6-K, Report of foreign issuer63
01.05.H.C. Wainwright cuts AC Immune SA target to $12; maintains buy123
30.04.AC Immune GAAP EPS of -CHF0.1934
30.04.AC Immune SA - 6-K, Report of foreign issuer13
30.04.AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update1.561AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive...
► Artikel lesen
13.03.AC Immune SA: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update523AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential...
► Artikel lesen
10.12.24AC Immune SA: AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome495AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,8